Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Monday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Truist Financial cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Finally, Royal Bank of Canada dropped their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Up 0.9 %

Shares of Marinus Pharmaceuticals stock opened at $0.54 on Monday. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $10.50. The firm has a fifty day simple moving average of $0.35 and a 200-day simple moving average of $1.01. The stock has a market capitalization of $29.65 million, a price-to-earnings ratio of -0.22 and a beta of 1.03.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRNS. Suvretta Capital Management LLC raised its stake in shares of Marinus Pharmaceuticals by 32.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after purchasing an additional 1,253,901 shares during the period. Franklin Resources Inc. lifted its stake in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after acquiring an additional 1,219,871 shares in the last quarter. abrdn plc lifted its stake in Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after acquiring an additional 1,578,329 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $813,000. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.